Yes, 30 million is absolute worst case scenario for dilution, which could only occur if the FDA needed a pivotal trial with 1000 patients or more and with the timeline for approval being extended well into 2027. I don't think that will happen but I always try to give the worst case scenario, which would IMO be $95 at FDA approval, and less dilution/shorter timelines would mean a higher share price.
Right now I believe we have 17.45 million shares fully diluted and, barring a buyout, I expect another raise of maybe $40-45 million AUD within the next 6 months or so, perhaps accompanied by an "IPO" on the Nasdaq.
Add to My Watchlist
What is My Watchlist?
